Piramal's Imaging Division Making the Invisible Visible

Piramal's Imaging Division, was recently created through the acquisition of worldwide rights for a molecular imaging research and development portfolio of Bayer Pharma AG. The portfolio includes rights to Florbetaben, a highly specialized molecule used in PET (Positron Emission Tomography) imaging to detect Beta-amyloid plaque which is a widely recognized marker for Alzheimer’s disease. Florbetaben has recently completed its Phase III clinical trials, the preliminary results of which have been presented in New Orleans at the American Academy of Neurology Annual Meeting on April 25th, 2012.